Two medicines, side by side
Candesartan vs irbesartan
Candesartan and irbesartan are both labeled for high blood pressure. Drugs@FDA records approvals of candesartan since 1998 and of irbesartan since 1997. Pharmacies paid $0.478 per candesartan cilexetil 16 mg tablet and $0.107 per irbesartan 150 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. How each works, in its label's words: Candesartan, “Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).”; Irbesartan, “Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).”
Check it at the source: the candesartan FDA label on DailyMed (effective January 15, 2026); the irbesartan FDA label on DailyMed (effective August 6, 2026).
Highlights of the candesartan record
Candesartan (Atacand) · label of January 15, 2026
FETAL TOXICITY When pregnancy is detected, discontinue candesartan cilexetil as soon as possible [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning.
Used for
From the label: indicationsCandesartan cilexetil is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). […]
On the market
- Earliest approval on file
- June 4, 1998
- Generic labelers
- 8 labelers
- Pharmacy cost
- $0.478 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 9
Highlights of the irbesartan record
Irbesartan (Avapro) · label of August 6, 2026
FETAL TOXICITY
When pregnancy is detected, discontinue irbesartan tablets as soon as possible [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )].
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning.
Used for
From the label: indicationsIrbesartan is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. […]
On the market
- Earliest approval on file
- September 30, 1997
- Generic labelers
- 23 labelers
- Pharmacy cost
- $0.107 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 10
Source: FDA drug labels via openFDA (Candesartan label of January 15, 2026, Irbesartan label of August 6, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do candesartan and irbesartan differ on the record?
How each works, in its label's words: Candesartan, “Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).”; Irbesartan, “Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).”
Both are in FDA's class angiotensin 2 receptor blockers.
Half-life, in each label's words: Candesartan, “The elimination half-life of candesartan is approximately 9 hours.”; Irbesartan, “The terminal elimination half-life of irbesartan averages 11 to 15 hours.”
Both labels carry a boxed warning; the records quote them.
Generics: candesartan since 2013; irbesartan since 2012 (Drugs@FDA).
| Candesartan | Irbesartan | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure | High blood pressure, Chronic kidney disease |
| Pharmacologic class | Angiotensin 2 Receptor Blocker | Angiotensin 2 Receptor Blocker |
| How it works (label) | Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). | Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). |
| Half-life (label) | The elimination half-life of candesartan is approximately 9 hours. | The terminal elimination half-life of irbesartan averages 11 to 15 hours. |
| Earliest approval on file (Drugs@FDA) | June 4, 1998 | September 30, 1997 |
| First generic approved | May 3, 2013 | March 30, 2012 |
| Generic labelers (NDC) | 8 labelers | 23 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.478 per tablet (Candesartan cilexetil 16 mg tablet) | $0.107 per tablet (Irbesartan 150 mg tablet) |
| 12-month price change | -15% | -8% |
| Boxed warning | Yes | Yes |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 9 | 10 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 60,889 | 44,400 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to candesartan
- every medicine labeled for the same conditions